Letter: which patients with hepatitis B virus-related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy?

Aliment Pharmacol Ther. 2016 Oct;44(8):908-10. doi: 10.1111/apt.13773.

Authors

Y-Y Liao¹, B-K Ahir², H-Y Mo¹, L-Q Li³, N-F Peng⁴

Affiliations

¹ Nutrition Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
² Section of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
³ Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
⁴ Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China. pengningfu@163.com.

PMID: 27634236
DOI: 10.1111/apt.13773

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antiviral Agents
Carcinoma, Hepatocellular*
Hepatitis B e Antigens
Hepatitis B virus*
Hepatitis B, Chronic
Humans
Liver Neoplasms

Substances

Antiviral Agents
Hepatitis B e Antigens